Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Meningococcal vaccine GSK134612
GlaxoSmithKline
Infections, Meningococcal
2 trials -
Nimenrix
GlaxoSmithKline
Infections, Meningococcal
1 trial -
Niraparib
GlaxoSmithKline
Neoplasms, Breast
1 trial -
Niraparib Placebo Tablets
GlaxoSmithKline
Neoplasms, Breast
1 trial -
Niraparib Placebo Tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion
GlaxoSmithKline
Lung Cancer, Non-Small Cell
1 trial -
Novolizer Salbutamol 100 microgrammes/dose, poudre pour inhalation, Sterile 0.9% (w/v) sodium chloride solution in single-use PFS
GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
1 trial -
PREDNISOLONE, Placebo for Depemokimab Injection, Placebo for Prednisolone
GlaxoSmithKline
Hypereosinophilic Syndrome (HES)
1 trial -
Placebo
GlaxoSmithKline
Infections, Papillomavirus
1 trial -
Placebo for Belimumab Solution for Injection, 200 mg/mL, Benlysta 200 mg solution for injection in pre-filled syringe.
GlaxoSmithKline
systemic sclerosis associated interstitial lung disease
1 trial -
Placebo for Bepirovirsen Solution for Injection 150 mg/mL
GlaxoSmithKline
Hepatitis B, Chronic
1 trial -
Placebo for Bepirovirsen Solution for Injection 150 mg/mL
GlaxoSmithKline
Hepatitis B, Chronic
1 trial -
Placebo for Mepolizumab Injection, MEPOLIZUMAB, Placebo for Depemokimab Injection
GlaxoSmithKline
Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy
1 trial -
Priorix - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze|Masern-Mumps-Röteln-Lebendimpfstoff, Priorix - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze|Masern-Mumps-Röteln-Lebendimpfstoff, VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff, Priorix - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze|Masern-Mumps-Röteln
GlaxoSmithKline
Varicella
1 trial -
RSV MAT
GlaxoSmithKline
Respiratory Syncytial Virus Infections
1 trial -
Rosiglitazone Extended Release 2mg
GlaxoSmithKline
Alzheimer's Disease
1 trial -
SB-497115-GR 12.5mg
GlaxoSmithKline
Chronic Idiopathic Thrombocytopenic Purpura
1 trial -
Salbutamol HFA-134a
GlaxoSmithKline
Asthma
1 trial -
Sterile 0.9% (w/v) sodium chloride solution in single-use PFS, Novolizer Salbutamol 100 microgrammes/dose, poudre pour inhalation
GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
1 trial -
TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion, TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion
GlaxoSmithKline
Neoplasms, Lung
1 trial -
Tafenoquine
GlaxoSmithKline
Malaria, Vivax
2 trials -
The IMAGINE study: A phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with Type 2 inflammation characterized by an eosinophilic phenotype utilizing quantitative high-resolution CT and bronchoscopic airway sampling in a sub study
GlaxoSmithKline
Asthma with type 2 inflammation characterized by an eosinophilic phenotype
1 trial -
Tritanrix-HepB/Hib-MenAC
GlaxoSmithKline
Whole Cell Pertussis
1 trial -
Tritanrix™-HepB/Hiberix™ Kft.
GlaxoSmithKline
Whole Cell Pertussis
1 trial -
VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff, VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff
GlaxoSmithKline
Varicella
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources